
Cuba Develops New Cancer Treatment Amid U.S. Embargo
Cuba's Molecular Immunology Center (CIM) has created a new therapeutic candidate, 2C12, for treating advanced melanoma. This drug aims to enhance the body's immune response against cancer cells. The development comes due to difficulties in accessing oncological drugs internationally, exacerbated by the U.S. embargo and economic crisis. The first clinical study will begin in Havana hospitals.4 sourcesSee all sources

